3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Burkitt Lymphoma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Leukemia, Biphenotypic, Acute
7
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
3
Leukemia, Myeloid, Accelerated Phase
3
Blast Crisis
3
Lymphoma, Mantle-Cell
2
Down Syndrome
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Renal Pelvis and Ureter Urothelial Carcinoma
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Rituximab
9
venetoclax
7
ibrutinib
7
Cyclophosphamide
7
Mycophenolic Acid
5
fludarabine phosphate
4
Whole-Body Irradiation
4
Sirolimus
4
zanubrutinib
3
pirtobrutinib
3
Peripheral Blood Stem Cell Transplantation
3
Dexamethasone
3
Cyclosporine
3
ixazomib
2
fludarabine
2
carfilzomib
2
acalabrutinib
2
Tacrolimus
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Busulfan
2
Bendamustine Hydrochloride
2
talquetamab
1
pembrolizumab
1
loncastuximab tesirine
1
brexucabtagene autoleucel
1
Vincristine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
merphos
×
90 days
×
Clear all
No trials found.